Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August? No pain, only gain for Vertex: FDA greenlights late-stage trial for nonopioid pain drug VistaGen can’t puff out phase 3 success for social anxiety nasal spray Astellas spends $70M on Bay Area gene therapy hub, bringing R&D work under one wing 'The Top Line' podcast: Biotech layoffs trend up, the pandemic's impact on generic drug sales, plus this week's headlines Tenet posts $38M profit for Q2 as major cyberattack drags earnings After decades on the NYSE, prosthetics maker Hanger to go private in $1.2B buyout J&J escapes $120M verdict after appellate court reverses loss in long-running talc case Justice Department cracks down on $1.2B worth of lab testing, telehealth fraud schemes Kardashian's back in Biohaven's new DTC campaign for 'all-in-one' migraine pill Nurtec Chutes & Ladders—Roche's Severin Schwan to relinquish CEO chair after 14 years Fierce Pharma Asia—Eisai's oncology unit cut; WuXi, Samsung expansions; BeiGene, Novartis' PD-1 pivot Featured Story | By Annalee Armstrong Will any of the three leading Alzheimer's disease therapies make it through their upcoming readouts? Executives from Biogen and Roche seem to be tempering expectations in second quarter earnings updates. Lilly is the next to report. read more |
| |
|---|
|
Top Stories By Gabrielle Masson After talks with the FDA, Vertex Pharmaceuticals has been given the go ahead to advance its non-opioid pain killer into phase 3 trials, which are set to begin in the last quarter of this year. read more By Max Bayer The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray. And the stakes just got even higher, after the results of the first of the two found that the company swung and missed. read more By Annalee Armstrong Astellas has rolled out plans for a $70 million innovation center on the West Coast. This sets up a consolidated shop in South San Francisco to house the Japanese pharma’s operations, which is currently scattered across the region. The biotechnology campus will be housed in a new 154,000 square foot building. read more By Teresa Carey This week on "The Top Line," we discuss the significant increase in layoffs and what that means for the biotech industry. Also under discussion is our special report on the top 10 companies by generic drugs sales. read more By Robert King Tenet Healthcare posted a $38 million profit for the second quarter of the year due in part to a debilitating cyberattack that led to a $100 million hit for the hospital chain. read more By Andrea Park Hanger agreed to be acquired by Patient Square Capital, a Silicon Valley healthcare investment firm that just last month joined in on the $890 million acquisition of biopharmaceutical developer Radius Health and, a month earlier, launched its own $300 million therapeutics-focused startup incubator. read more By Fraiser Kansteiner Tuesday, the appellate branch of the New York Supreme Court reversed an earlier decision in favor of plaintiff Donna Olson, who claimed her lifelong use of J&J’s talc caused her to develop mesothelioma. With a win in hand, J&J is also off the hook to pay Olson damages of $120 million, which were reduced from an original award of $325 million. read more By Andrea Park According to the DOJ, many of the fraudulent telemedicine referrals included orders for expensive genetic tests for cardiovascular conditions and cancer. read more By Natalie Missakian Biohaven is hammering home the “all in one” simplicity of Nurtec ODT to treat and prevent migraine in a new campaign that brings back reality star, influencer and entrepreneur Khloe Kardashian as celebrity spokeswoman. read more By Gabrielle Masson,Max Bayer For the first time in 14 years, Roche has a new CEO taking the reins. The Swiss pharma powerhouse has officially confirmed that Thomas Schinecker, Ph.D., will replace Severin Schwan, effective March 15, 2023. read more By Angus Liu Eisai is shutting down an oncology venture for good. WuXi Biologics and Samsung Biologics are making big investments in Asia. Novartis has ditched a plan for a PD-1 monotherapy filing in non-small cell lung cancer. And more. read more | | YOU vs. “UNSOLVABLE” PROBLEMS Let’s solve patient needs together. Turn promise into reality and become part of something bigger, today. Explore meaningful careers here. |
|---|
Resources Sponsored by: NetApp Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: Lumanity Join us, as we explore the commercial readiness challenges and practical realities of driving a successful launch in the cell and gene therapy space. Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Free Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ | 